Building long-lasting hyaluronic acid where the body needs it - through chemistry, not a syringe.
Hyaluronic acid is one of the most useful molecules in modern medicine and beauty. It cushions joints, lubricates eyes, and plumps skin. It is also stubbornly difficult to use. The molecule is too large to slip through skin on its own, and once it is inside the body, enzymes break it down within days. For decades the industry's answer was blunt: load pre-formed HA into a syringe and inject it, over and over.
Fount Bio, a life-science company founded in 2018 and headquartered in Somerville, Massachusetts, was built to break that pattern. Rather than delivering finished hyaluronic acid, Fount Bio delivers the building blocks - and lets them assemble into a durable HA matrix directly inside the target tissue. The company calls the underlying technology the Flī-HA platform, short for functional-ligand hyaluronic acid.
The approach rests on bioorthogonal chemistry, the field of fast, selective "click" reactions honored with the 2022 Nobel Prize in Chemistry. Fount Bio applies those reactions inside living tissue, where its HA precursors transform into a high-molecular-weight, biostable matrix in situ. The result is a form of hyaluronic acid that can be delivered topically and stays put.
It is a small team - roughly nine people - pursuing a large idea. In February 2024 that idea earned outside validation when the company's lead product, Flī-Derm, was named Innovation of the Year at the IMCAS World Congress in Paris.
The problem Fount Bio solves is mechanical as much as chemical: get hyaluronic acid where it is needed, then make it last. The Flī-HA platform does it in three moves.
HA building blocks are applied as a liquid and carried into the tissue with gentle assisted delivery - no injection of pre-formed filler.
Inside the tissue, bioorthogonal "click" chemistry triggers rapid assembly of the building blocks into a high-molecular-weight HA network.
The resulting matrix is biostable, resisting the rapid enzymatic breakdown that limits conventional exogenous HA.
Most competitors, from injectable dermal fillers to topical HA serums, deliver hyaluronic acid that is already made. Fount Bio's wager is that building the molecule on site changes the whole equation.
| Feature | Conventional HA fillers & serums | Fount Bio Flī-HA |
|---|---|---|
| Delivery | Injection of pre-formed HA | Topical liquid, needle-free |
| Where HA forms | Manufactured before use | Built in situ, inside tissue |
| Durability | Degrades relatively quickly | Biostable, long-duration matrix |
| Adaptability | Fixed formulation | Tunable per application |
| Reach | Skin-focused | Skin, eyes, joints, mucosa |
Comparison reflects Fount Bio's public description of its platform versus standard categories of HA products. Clinical and commercial performance continues to be evaluated.
The proprietary bioorthogonal-chemistry engine that delivers HA building blocks and assembles them into a biostable matrix in situ. Tunable across tissue types, it is the foundation for everything else.
A needle-free liquid for aesthetic dermatology that builds durable HA within the dermis. In a blinded clinical study it significantly reduced fine lines and wrinkles versus control, with strong safety and tolerability.
Earlier-stage programs apply the same platform to ophthalmology, women's health, joints and mucosal tissues - one core technology pointed at several markets.
Fount Bio pairs two complementary founders. Samir Mitragotri, Ph.D., a Harvard professor recognized for his work in skin delivery and bioengineering, supplies the scientific foundation and now serves as senior scientific advisor. Doug Levinson, Ph.D., a serial entrepreneur with a 25-year track record building life-science companies, runs the business as co-founder and CEO.
That split - deep research on one side, operating experience on the other - is a familiar formula for deep-tech ventures, and a common failure point when the two do not mesh. At Fount Bio the board pairs the founders with investors from Morningside Ventures.
As a business, Fount Bio operates as a platform-based life-science company. It develops proprietary HA-matrix products in-house, advancing lead assets like Flī-Derm through clinical validation, while the tunable Flī-HA platform gives it optionality across aesthetic, consumer-beauty and medical categories - either as products it builds or technology it can extend.
Its first customers are aesthetic-dermatology and medical-aesthetics practitioners and their patients, reached through Flī-Derm. Further out, the company sees consumers seeking needle-free HA beauty products, and patients across ophthalmology, women's health and joint indications. The company remains clinical-stage and pre-commercial.
Fount Bio sits at the intersection of biomaterials, drug delivery and aesthetic medicine - a crowded market where its edge is mechanism rather than marketing.
Doug Levinson and Harvard bioengineer Samir Mitragotri launch the company to commercialize glycopolymer and bioorthogonal-chemistry advances for tissue delivery of HA.
An $8.16M round advances the Flī-HA platform toward clinical proof of concept; Morningside partners join the board.
Flī-Derm shows significant wrinkle reduction in a blinded study and wins Innovation of the Year at IMCAS World Congress 2024 in Paris.
Flī-HA is built on bioorthogonal "click" chemistry - the field recognized with the 2022 Nobel Prize in Chemistry.
Flī-Derm delivers filler-like benefits by building HA inside the skin instead of injecting it pre-formed.
"Fount" is shared online with an unrelated human-performance startup - a common source of mixed-up social handles.
The same tunable platform targets markets as different as wrinkles, eyes, joints and mucosal tissue.
Fount Bio keeps a low public profile. Start with the platform pages, then search these curated queries for talks, demos and coverage as they surface.